Category Archives: brigatinib-Alunbrig from Takeda

Patients can live a median of 6.8 years after stage 4 diagnosis

A study of 110 patients at the University of Colorado found that 50% of patients live 6.8 years or longer. These were patients who had access to multiple ALK inhibitors through clinical trials at that research University. That University also … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Research | Leave a comment

Brigatinib vs Crizotinib phase 3 interim results

In September 2018, Takeda reported a pre-designated first interim analysis of a phase 3 trial in the New England Journal of Medicine. The study enrolled 275 ALK inhibitor naive patients. Half got Brigatinib and half got Crizotinib. For Brigatinib: at … Continue reading

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, crizotinib - Xalkori from Pfizer, Lung cancer, Research | Leave a comment

FDA conditionally approves Loralatinib

As of 11-2-2018 the FDA conditionally approved Loralatinib. It’s brand name is Lorbrena. The approval is for Loralatinib treatment for patients: 1) as a third line after crizotinib and one other ALK inhibitor (basically Brigatinib), or 2) as a second line treatment … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Great page with very high quality info on AlK & AlK inhibitors

Below is a link to a page that provides comprehensive regularly updated info written by two ALK research oncologists Dr. Alice Shaw and Ben Solomon, Phd (then edited by three people). It is written for an audience of doctors and … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments | Leave a comment

FDA approves brigatinib

On April 28, 2017 the FDA granted Takeda (formerly Ariad) approval for Alunbrig (brigatinib) to be sold in the US to patients who are resistant to Crizotinib.

Posted in brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Ariad files FDA application and gets acquired

As of August 30, 2016 Arriad had filed its new drug application with the FDA for brigatinib. As of Oct 31, 2016 the FDA granted ARIAD’s request for Priority Review and has set an action date of April 29, 2017. As of January … Continue reading

Posted in brigatinib-Alunbrig from Takeda, Lung cancer, Regulatory applications & approvals | Leave a comment

Update on Novartis and Ariad trials

As of Dec. 6, 2016 Novartis and Ariad announced research updates In Phase III study by Novartis on Zykadia® (ceritinib) as a first-line treatment, they found a 45% reduction in the risk of disease progression. The study found a median progression free survival … Continue reading

Posted in Anaplastic Large-Cell Lymphomas, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research | Leave a comment

Abstract 9007 on Brigatinib update

The initial write up of the abstract 9007 was posted on May 19. This update covers about 3 more months of data and brain mets. Arm A (90 mg) median Progression Free Survival (PFS) increased from 8.8 months to 9.2 … Continue reading

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Research | Leave a comment

Outcomes for ALK+ patients

Abstract e20550 is from Spain and involves 49 patients. Patients took 6 different ALK inhibitors. The abstract concluded “ALK+ patients who received targeted agents have prolonged survival despite brain metastases…. ALK inhibitors improve intracranial response rate and survival.”

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Britatinib abstract

Abstract 9007 covers the Phase 2 trial (ALTA) comparing two dosing schemes. There were 222 patients who had progressed on Crizotinib. Results where as of 12-7-15. Arm A received 90 mg straight through.  Arm Breceived 90 mg for the first … Continue reading

Posted in brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment